Jim Simons Delcath Systems, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 256,200 shares of DCTH stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

256,200

Previous 178,000 43.93%

Holding current value

$2.29 Million

Previous $2.42 Million 13.8%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$10.01 - $12.76 $782,782 - $997,832	78,200 Added 43.93%	256,200 $2.75 Million
Q2 2025 Aug 13, 2025	BUY	$10.39 - $18.1 $1.11 Million - $1.93 Million	106,700 Added 149.65%	178,000 $2.42 Million
Q1 2025 May 14, 2025	SELL	$11.43 - $16.45 $765,147 - $1.1 Million	-66,942 Reduced 48.42%	71,300 $907,000
Q4 2024 Feb 13, 2025	SELL	$8.32 - $12.64 $1.44 Million - $2.19 Million	-173,558 Reduced 55.66%	138,242 $1.63 Million
Q3 2024 Nov 13, 2024	BUY	$7.36 - $11.0 $1.68 Million - $2.52 Million	228,900 Added 276.12%	311,800 $2.82 Million
Q2 2024 Aug 09, 2024	BUY	$4.47 - $8.37 $370,563 - $693,872	82,900 New	82,900 $693,000
Q2 2023 Aug 11, 2023	BUY	$5.38 - $7.96 $50,572 - $74,824	9,400 Added 77.69%	21,500 $125,000
Q1 2023 May 12, 2023	BUY	$3.46 - $6.0 $41,866 - $72,600	12,100 New	12,100 $70,000
Q2 2021 Aug 13, 2021	SELL	$9.54 - $15.1 $151,686 - $240,090	-15,900 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$12.42 - $23.81 $1.06 Million - $2.03 Million	-85,376 Reduced 84.3%	15,900 $197,000
Q4 2020 Feb 10, 2021	BUY	$10.55 - $18.69 $1.07 Million - $1.89 Million	101,276 New	101,276 $1.82 Million

Others Institutions Holding DCTH

# of Institutions

129

Shares Held

13.1M

Call Options Held

133K

Put Options Held

159K

View Full List

About DELCATH SYSTEMS, INC.

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $76.8M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

More about DCTH

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account